T H O M S O N S C I E N T I F I C Ann Wescott April 8, 2008 Prous Science Update SLA DPHT Spring Meeting 2008

Copyright 2008 Thomson Corporation 2 T H O M S O N S C I E N T I F I C Integrity Foundations Launched in 2001; building on more than 40 years experience: –Scientific Journals: Drugs of the Future, Drug Data Report, Drugs of Today, Drug News & Perspectives, Methods and Findings in Experimental and Clinical Pharmacology –Databases: CIPSLINE, MDDR, Drug Data Report on CD-ROM, Trilogy, Ensemble, MFline, Synthline, DailyDrugNews.com More than a pipeline database: Targets & Pathways, Genomics, Synthesis, Experimental Pharmacology, PK, Metabolism, Clinical Studies, Disease Briefings And more to come: Predictive Pharmacology Module, IntegrityChannel, … Integrity core values: Coherence, consistency, curation, integration

Copyright 2008 Thomson Corporation 3 T H O M S O N S C I E N T I F I C Integrity Content April 2008 Number of Records 278,000 (94% with chemical structure) 2,050 target records 7,700 gene records 18,500 schemes; 75,000 intermediates 691,000 values 356,000 values 84,000 records 98 executive reports 2,460 companies 820,000 references 105,000 patent families Knowledge Area Drugs & Biologics Targets & Pathways Genomics Organic Synthesis Experimental Pharmacology Pharmacokinetics / Metabolism Clinical Studies Disease Briefings Companies & Research Inst. Literature Patents

Copyright 2008 Thomson Corporation 4 T H O M S O N S C I E N T I F I C Integrity Content Growth

Copyright 2008 Thomson Corporation 5 T H O M S O N S C I E N T I F I C Integrity Content Growth

Copyright 2008 Thomson Corporation 6 T H O M S O N S C I E N T I F I C Integrity Evolution Integrity is continuously evolving and growing: –2002: 3 new releases, 12 major enhancements –2003: 2 new releases, 14 major enhancements –2004: 2 new releases, 6 major enhancements –2005: 3 new releases, 18 major enhancements –2006: 3 new releases, 10 major enhancements –2007: 4 new releases, 11 major enhancements –2008: 3 new releases, …

Copyright 2008 Thomson Corporation 7 T H O M S O N S C I E N T I F I C Key New Features 2007 New Knowledge Areas New product search & display fields by client request Related criteria searching Integrity Reports New search options from Integrity Home Page Patents Knowledge Area additions Filter by Statistics/Chart enhancements More structure search options in Organic Synthesis Integrity Metrics

Copyright 2008 Thomson Corporation 8 T H O M S O N S C I E N T I F I C

Copyright 2008 Thomson Corporation 9 T H O M S O N S C I E N T I F I C

Copyright 2008 Thomson Corporation 10 T H O M S O N S C I E N T I F I C

Copyright 2008 Thomson Corporation 11 T H O M S O N S C I E N T I F I C

Copyright 2008 Thomson Corporation 12 T H O M S O N S C I E N T I F I C

Copyright 2008 Thomson Corporation 13 T H O M S O N S C I E N T I F I C

Copyright 2008 Thomson Corporation 14 T H O M S O N S C I E N T I F I C

Copyright 2008 Thomson Corporation 15 T H O M S O N S C I E N T I F I C

Copyright 2008 Thomson Corporation 16 T H O M S O N S C I E N T I F I C

Copyright 2008 Thomson Corporation 17 T H O M S O N S C I E N T I F I C Whats Next? Release : Integrity Predictive Pharmacology Module –Collection of molecular properties and predictive pharmacology data accessible through visualization tools aimed at expanding existing knowledge within the system –Separately licensed add-on to Integrity

Copyright 2008 Thomson Corporation 18 T H O M S O N S C I E N T I F I C Key Bottlenecks in Pharma R&D Predictive Pharmacology Predictive Toxicology Identification of Biomarkers Patient Recruitment Validation of Biomarkers Risk assessment with regulatory authorities

Copyright 2008 Thomson Corporation 19 T H O M S O N S C I E N T I F I C Predictive Pharmacology Module Why Predictive Pharmacology? –Pharmacology: studies the effects of drug activity on biological systems –Predictive Pharmacology attempts to elucidate the behavior of bioactive compounds behavior not originally considered by the inventor Benefits of Predictive Pharmacology –Rapidly evolving as a key component for increasing drug R&D productivity by its ability to: Identify potential new uses for drugs launched or under active development Generate new leads faster Create drug discovery hypotheses

Copyright 2008 Thomson Corporation 20 T H O M S O N S C I E N T I F I C

Copyright 2008 Thomson Corporation 21 T H O M S O N S C I E N T I F I C

Copyright 2008 Thomson Corporation 22 T H O M S O N S C I E N T I F I C

Copyright 2008 Thomson Corporation 23 T H O M S O N S C I E N T I F I C

Copyright 2008 Thomson Corporation 24 T H O M S O N S C I E N T I F I C

Copyright 2008 Thomson Corporation 25 T H O M S O N S C I E N T I F I C

Copyright 2008 Thomson Corporation 26 T H O M S O N S C I E N T I F I C What Else Is Next? New Biomarkers Initiative from Thomson Scientific

Copyright 2008 Thomson Corporation 27 T H O M S O N S C I E N T I F I C What Is a Biomarker? Biomarker: A characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacologic responses to a therapeutic intervention. From: Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69(3): 89-95

Copyright 2008 Thomson Corporation 28 T H O M S O N S C I E N T I F I C Why Are Biomarkers Important? Biomarkers constitute an essential piece in the landscape of modern medicine and may be critical for: –Validating proof of concept in animal models –Facilitating early diagnosis and selection for therapy –Staging disease –Defining individualized response to drug treatment –Measuring disease prognosis –Determining early efficacy –Monitoring safety

Copyright 2008 Thomson Corporation 29 T H O M S O N S C I E N T I F I C Our Data Proposition Thomson Scientifics biomarkers initiative will form a single, authoritative and trusted repository of knowledge covering biomarkers in research and in use. It will place this knowledge in context, enabling users to assess at a glance the relative importance of different biomarkers. Our initiative will expand this to provide a comprehensive, up-to-date body of timely, reliable knowledge on a wide range of biomarkers in different lifecycle phases and disciplines.

Copyright 2008 Thomson Corporation 30 T H O M S O N S C I E N T I F I C Our Data Proposition Biomarker records will include: –Biomarker name(s) –Classification –Biological entities / process involved –Associated drugs –Role or utility –Pipeline status –Validity –Measurement techniques –Diagnostic kits (where available)